Terlipressin is a Synthetic Peptide owned by Orphan Therapeutics, and is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing.

Terlipressin is an agonist of arginine vasopressin receptor 1A, arginine vasopressin receptor 1B, and arginine vasopressin receptor 2. The vasoconstrictive effects are mediated by vascular V1 receptors. Vascular V1 receptors are directly coupled to phopholipase C, resulting in release of calcium leading to vasoconstriction. It arrests bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.

The revenue for Terlipressin is expected to reach a total of $5.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Terlipressin NPV Report.

Terlipressin is currently owned by Orphan Therapeutics. Mallinckrodt is the other company associated in development or marketing of Terlipressin.

Terlipressin Overview

Lucassin (terlipressin, Terlivaz) is an analogue of vasopressin  acts as vasoconstrictor agent. It is formulated as solution for intravenous and intravenous bolus route of administration. Lucassin is indicated for the treatment of gastrointestinal bleeding from ruptured esophageal and gastric varices, and emergency treatment of hepatorenal syndrome type 1. Telivaz is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

It is also under development for treatment of hepatorenal syndrome (HRS) type 1.

Mallinckrodt Overview

Mallinckrodt develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$2,208.8 million for the fiscal year ended December 2021 (FY2021), a decrease of 19.7% over FY2020. The operating loss of the company was US$631.1 million in FY2021, compared to an operating loss of US$713 million in FY2020. The net loss of the company was US$717.4 million in FY2021, compared to a net loss of US$944.6 million in FY2020.

Quick View – Terlipressin

Report Segments
  • Innovator (NME)
Drug Name
  • Terlipressin
Administration Pathway
  • Intravenous
  • Intravenous Bolus
Therapeutic Areas
  • Gastrointestinal
Key Companies
  • Sponsor Company: Orphan Therapeutics
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.